Tradestie Institutional Equity Comparison Engine
ACRS vs AVDL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AVDL Overall Edge
AVDL Captures Institutional Edge (4โ0 Pillars ยท 9โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avadel Pharmaceuticals plc Ordinary Share (AVDL) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ACRS trades at N/M Forward P/E with -1412.4% operating margin (-55.1% YoY revenue) versus AVDL at 28.8x Forward P/E and 2.5% operating margin (+54.9% YoY). In options structure, ACRS sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro) against AVDL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
AVDL
ACRS N/M vs AVDL 28.8x Fwd P/E
Growth & Margin Winner
AVDL
Op Margin -1412.4% vs 2.5% ยท YoY -55.1% vs +54.9%
Momentum & Technical Winner
AVDL
1Y +39.8% vs +138.1% ยท 52W Pos 26% vs 89%
Options & Structure Winner
AVDL
BREAKDOWN (<1st %ile IV) vs UNCLASSIFIED (<1st %ile IV)
ACRS
NASDAQ
Aclaris Therapeutics, Inc.
Pharmaceutical Preparations
$3.44
-1.71% 1D
Market Cap
$555.1M
1M Return
-10.18%
1Y Return
+39.84%
Forward P/E
N/M
Unified AI Score
45.2 / 100
HOLD
Tech 42.0
Fund 57.0
Flow 64.0
Mom 70.0
AVDL
NASDAQ
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap
$2.1B
1M Return
+0.65%
1Y Return
+138.06%
Forward P/E
28.8x
Unified AI Score
62.9 / 100
BUY
Tech 75.0
Fund 60.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ACRS +39.84%
AVDL +138.06%
Spread: +44.12 pp (ACRS Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ACRS TTM Op. Margin: -1412.4%
AVDL TTM Op. Margin: 2.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACRS vs AVDL. Trailing 12-month operating profitability (ACRS -1412.4% vs AVDL 2.5%) and valuation multiples (ACRS N/M vs AVDL 28.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ACRS | AVDL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $555.1M | $2.1B | Larger Scale | AVDL |
| Trailing P/E Ratio Valuation | N/M | 16.8x | Lower Multiple | AVDL |
| Forward P/E Ratio Valuation | N/M | 28.8x | Lower Multiple | AVDL |
| Revenue Growth (YoY) Growth | -55.1% | +54.9% | Higher Growth | AVDL |
| Operating Margin (TTM) Profitability | -1412.4% | 2.5% | Higher Margin | AVDL |
| Net Profit Margin Profitability | 0.0% | -0.1% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -55.5% | -0.3% | Higher ROE | AVDL |
| 52-Week Range Position Momentum | 26% ($2โ$7) | 89% ($6โ$24) | Stronger Trend | AVDL |
| Beta / 30D Volatility Risk Regime | 1.42ฮฒ ยท 69% Vol | 0.14ฮฒ ยท 2% Vol | Lower Realized Risk | AVDL |
| Unified Institutional Score Composite Signal | 45.2 / 100 (HOLD) | 62.9 / 100 (BUY) | Higher Composite | AVDL |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ACRS vs AVDL Buy Guide
ACRS
BREAKDOWN
62d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
AVDL
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ACRS nor AVDL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.